Summary of Use during Lactation

No information is available on the clinical use of benralizumab during breastfeeding. Because benralizumab is a large protein molecule with a molecular weight of about 150,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. A task force respiratory experts from Europe, Australia and New Zealand found that benralizumab is possibly safe during breastfeeding.[1] Until more data become available, benralizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[2]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Asthma) Omalizumab, Mepolizumab

References

1.

Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020;55:1901208. [PubMed: 31699837]

2.

Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350–66. [PubMed: 36931808]

Substance Name

Benralizumab

CAS Registry Number

1044511-01-4

Drug Class

Breast Feeding

Lactation

Milk, Human

Anti-Allergic Agents

Anti-Asthmatic Agents

Antibodies, Monoclonal, Humanized